Aktis Oncology, Inc. Common stock (AKTS) Stock Price
AKTSStock
$15.06−82.46%52W
Market Cap$837.63M
P/E—
PEG Ratio—
Div yield—
Beta165.21
AKTS Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-25.49%
Price vs S&P 500 (4W)-28.40%
VGM Score51.20
AKTS Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.43 | -$0.44 | -2.15%(-$0.01) | |
| Q1 2026 | -$0.33 | -$0.38 | -15.15%(-$0.05) |
AKTS Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.33
4.38
4.38
4.40
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
AKTSAktis Oncology, Inc. Common stock | — | B | D | 63.9x | 49.9% | -11.6% | — | $15.06 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Aktis Oncology, Inc. Common stock
Aktis Oncology is a clinical-stage oncology company developing targeted alpha radiopharmaceuticals for solid tumors, including breast, lung, colorectal, bladder, and liver cancers. The company focuses on expanding access to large patient populations not addressed by existing platform technologies. Its pipeline includes AKY-1189 and AKY-2519.